Assuntos
Animais , Camundongos , Autoimunidade , Linfócitos B/citologia , Linfócitos B/imunologia , Cisteína Endopeptidases/imunologia , Cisteína Endopeptidases/metabolismo , Peptídeos e Proteínas de Sinalização Intracelular/imunologia , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , /imunologia , /metabolismo , Linfócitos B/enzimologia , Linhagem da Célula , Sobrevivência Celular , Cisteína Endopeptidases/deficiência , Homeostase , Peptídeos e Proteínas de Sinalização Intracelular/deficiência , Camundongos Knockout , NF-kappa B/metabolismo , Transdução de SinaisRESUMO
Recently, new treatment approaches have been developed to target the host component of periodontal disease. This review aims at providing updated information on host-modulating therapies, focusing on treatment strategies for inhibiting signal transduction pathways involved in inflammation. Pharmacological inhibitors of MAPK, NFκB and JAK/STAT pathways are being developed to manage rheumatoid arthritis, periodontal disease and other inflammatory diseases. Through these agents, inflammatory mediators can be inhibited at cell signaling level, interfering on transcription factors activation and inflammatory gene expression. Although these drugs offer great potential to modulate host response, their main limitations are lack of specificity and developments of side effects. After overcoming these limitations, adjunctive host modulating drugs will provide new therapeutic strategies for periodontal treatment.